this study we transferred the alphoid tetO -HAC into mouse ES cells and assessed whether the presence of this extra chromosome affects their pluripotent properties. Alphoid tetO -HACbearing ES cells were indistinguishable from their wild-type counterparts: they retained selfrenewal potential and full capacity for multilineage differentiation during mouse development, whereas the HAC itself was mitotically and transcriptionally stable during this process. Our data provide the first example of fully synthetic DNA behaving like a normal chromosome in cells of living animals. It also opens a new perspective into functional genetic studies in laboratory animals as well as stem cell-based regenerative medicine.
INTRODUCTION
Gene therapy remains a challenging approach for the treatment of various disorders, including monogenic and polygenic diseases. Gene therapy requires either the correction of a defective gene or provision of a wild-type copy of a damaged gene. The former can be addressed using recently developed gene editing tools: Zinc Finger Nucleases (ZFNs), Transcription ActivatorLike Effector Nucleases (TALENs), and, most potently, the Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CAS9. 1 For the latter approach, virus-based delivery systems are usually used, but there no available system that simultaneously meets all the criteria of an ideal gene therapy vector: high cloning capacity, episomal maintenance, stable long-term expression of a gene of interest in quiescent as well as dividing cells, and lack of toxicity or immunogenicity. Typically, some of these criteria are achieved with a trade-off of others. All of them, however, are readily met by one class of DNA vectors, the Human Artificial Chromosomes (HACs).
Most characterized HACs have been generated by a top-down approach involving truncation of various human chromosomes, 2,3 which, strictly speaking, makes them modified natural chromosomes (mini-chromosomes) rather than artificial ones. All these HACs are maintained as episomes and are mitotically stable. The most advanced HAC of this type (21HAC) was generated by truncation of human chromosome 21. 4 The 21HAC, presumably free of any known genes, has been further modified to contain multiple recombination sites to facilitate loading of sequences of interest. 5 Importantly, this HAC has demonstrated its utility as a high capacity gene therapy vector in mouse models of muscular dystrophies. 3, [6] [7] [8] This HAC has also been successfully used to deliver reprogramming factors, but its subsequent removal from de novo generated iPS cells is quite problematic and relies on spontaneous loss during mitotic divisions, which is extremely rare.
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A novel, truly artificial HAC has recently come to the fore as a highly promising vector system. This HAC has been assembled de novo from a synthetic alphoid DNA array with embedded tetracycline operator (tetO) that binds tet-repressor fusion proteins, providing the option to incorporate conditional inhibition of kinetochore assembly, resulting in subsequent loss of the HAC from populations of dividing cells. [10] [11] [12] [13] The bottom-up assembled alphoid tetO -HAC vector therefore has a significant advantage over top-down constructed HACs because it can be deployed in a hit-and-run fashion, which is the preferred option for several applications. 
MATERIALS AND METHODS

Ethics statement
All animal procedures were performed according to the guidelines for the humane use of laboratory animals, with standards corresponding to those prescribed by the American Physiological Society. Mouse work was performed strictly in agreement with the animal protection legislation acts of the Russian Federation, and was approved as humane use of laboratory animals by the Institute's Ethical Board.
Cell culture
All media and components were from Life Technologies and Sigma, unless indicated. CHO (Chinese Hamster Ovary) cells were routinely maintained in 5% CO 2 atmosphere in DMEM/F12 medium supplemented with 10% Fetal Bovine Serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine. Mouse ES cells (E14 Tg2a, BayGenomics) were cultured on gelatin-coated dishes in Knockout-DMEM supplemented with 15% ES cellqualified fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM Lglutamine, non-essential amino acids, 50 μM β-mercaptoethanol, 1000 U/ml LIF (PAA). For routine passaging, cells were rinsed in PBS, treated with TrypLE and split 1:4. Mouse tail-tip fibroblasts were grown in DMEM containing 1 g/l glucose (Gibco, Germany), supplemented with 10% Fetal Bovine Serum, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2 mM Lglutamine.
Microcell-mediated chromosome transfer (ММСТ)
This procedure was performed as described elsewhere. 15, 17 Microcells were collected from 
Teratoma formation test
Mouse ES cell carrying HAC (clones A1, B1, C1, D1, F1) exponentially growing on gelatin coated dishes in ES medium, were harvested with TrypLE express (Gibco), resuspended in PBS and injected subcutaneously (1×10 6 cells) into athymic CD-1 NUDE mice. After 4-6 weeks teratomas were removed from euthanized animals and processed for histological and immunohistochemical analysis.
Immunohistochemistry
Teratomas were excised and fixed in 4% PFA prepared on PBS at 4ºC overnight. After washing in PBS (2 times, each for 2 hrs) they were dehydrated in an ethanol series (70-100%) and isobutanol : paraffin series (2:1-1:1-1:2) and were embedded in paraffin (Sigma). 7 μm sections were prepared using Leitz 1208 microtome (Germany). Paraffin sections were washed in xylene, rehydrated through an ethanol series (100-70%) and washed in 0.1% Tween20-PBS.
After blocking in 1% BSA-0.1% Tween20-PBS for 30 minutes sections were incubated overnight with primary antibodies against GFP (Life Technologies A-11120) at 4°C. Then, sections were washed several times in 0.1% Tween20-PBS and incubated with secondary antibodies conjugated with Alexa488 (Abcam ab150113) for 3 hrs at room temperature (RT).
After that, sections were washed in 0.1% Tween20-PBS, counterstained with DAPI and embedded into an anti-fading media under coverslips. Primary and secondary antibodies were diluted in 1% BSA-0.1% Tween20-PBS, respectively, 1:200 and 1:500. The samples were examined on BZ-9000 (Keyence) or Axiovert 40 (Zeiss) fluorescent microscopes.
Preparation of metaphase spreads
Metaphase spreads were prepared as previously described in refs. RT in dust-free place. For preparation of metaphases from tail-tip fibroblasts, the cells were cultured overnight in 0.05 μg/ml colcemid at 37°C in 5% CO 2 atmosphere and processed as described above.
FISH
Fluorescent in situ hybridization analysis was performed as described elsewhere with modifications. The construct containing the alphoid-tetO array p3. 
Blastocyst injection
Mouse ES cell carrying HAC (clones B1, C1) were trypsinized, resuspended in a small amount of ES-medium and kept on ice until the injection. Embryos were recovered by flushing the uterine horns with M2 medium (Sigma) from superovulated 23-25 days old C57Bl/6 inbred female mice at 3.5 dpc, as previously described. 21 15-17 ES-HAC cells were injected per blastocyst and embryos were transferred into uterine horns of 2.5 dpc or to the oviducts of 0.5 dpc anesthetized pseudopregnant CB6F1 females (10-12 embryos per recipient).
Isolation of mouse tail-tip fibroblasts
Tail tip (approximately1 cm) biopsies were minced by scalpel to small pieces, incubated with 1 mg/ml collagenase IV (Sigma) for 15 min at 37°C, washed with PBS, additionally treated with TrypLE express (Life Technologies) for 20 min at 37°C, resuspended in fibroblast culture medium, collected by centrifugation, resuspended in the same medium and plated in a well of 6-well plate. Culture media was changed every second day. Five morphologically undifferentiated EGFP-HAC-bearing ES cell colonies ( Figure   1C , Figure S2 ) selected in blasticidin (Bsd)-containing medium were picked, expanded, and analyzed by FISH ( Figure 1D ). Two EGFP-HAC ES cell clones (B1 and C1) that showed mostly normal male karyotype cells (40XY) and autonomic EGFP-HAC ( Figure 1D ) were chosen for further analysis. The other three clones showed either abnormal karyotypes or HAC integration into host chromosomes, and were discarded. ES cell clones B1 and C1 were morphologically indistinguishable from their wild-type counterpart, stably expressed EGFP for at least 15 passages ( Figure S3) , and expressed the pluripotency markers Oct4, Nanog, and SSEA-1 ( Figure 1E ). When injected into NUDE mice, these cells formed teratomas with clearly visible differentiated cell types belonging to all three germ layers. Immunostaining revealed widespread expression of EGFP in the germ layers throughout the tumor (Figure 2 ).
RESULTS
The
These data taken together suggest that the presence of the alphoid tetO -HAC in mouse ES cells does not affect pluripotent properties such as self-renewal and multilineage differentiation capacity. In addition, this alphoid tetO -HAC is mitotically stable and maintains the expression of the constituent EGFP marker gene throughout multiple cell divisions and processes of differentiation into virtually all cellular types present in teratomas.
Our next goal was to assess the ability of the EGFP-HAC-bearing ES cells to contribute to embryonic development following their injection into mouse blastocysts ( Figure S4 ), and to evaluate the mitotic and transcriptional robustness of this HAC during this process. First, we analyzed 10.5 dpc chimeric embryos and found widespread EGFP-HAC-bearing ES cell descendants ( Figure 3A) . We next examined live born chimeric mice ( Figure 3B ). EGFP-HAC was found to be maintained as an autonomous chromosome unit, assessed by FISH analysis of primary fibroblast cultures derived from the tail tips of chimeric mice ( Figure 3C and D) . We 
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